Literature DB >> 3710068

Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit.

B I Cohen, A F Hofmann, E H Mosbach, R J Stenger, M A Rothschild, L R Hagey, Y B Yoon.   

Abstract

Nor-ursodeoxycholate, the C23 analogue of ursodeoxycholate, is a potent choleretic agent in rodents when given acutely but, to be used in humans, chronic toxicity studies are required. In the rabbit, ingestion of ursodeoxycholate or chenodeoxycholate leads to accumulation of lithocholate, its major bacterial metabolite, in biliary bile acids, which causes inflammation in portal tracts of the liver and bile duct proliferation. To test whether chronic administration of nor-ursodeoxycholate would cause an analogous accumulation of nor-lithocholate and hepatotoxicity, rabbits were fed a Chow diet containing nor-ursodeoxycholate (5 or 50 mg/day): control groups received Chow alone, and "disease control" groups received Chow plus ursodeoxycholate or Chow plus chenodeoxycholate. After 3 wk, animals were killed, liver sections were interpreted by a pathologist, and the steroid moiety of the glycine (and taurine) conjugates of gallbladder bile acids were analyzed by high-pressure liquid chromatography. Ingestion of nor-ursodeoxycholate did not cause hepatotoxicity, and neither it nor its presumed metabolite, nor-lithocholate, accumulated in biliary bile acids. To explain this unexpected finding, the hepatic metabolism of nor-ursodeoxycholate was investigated in biliary fistula rabbits. Nor-ursodeoxycholate was well absorbed from the intestine and secreted in the bile as a glucuronide as well as the unchanged compound, but conjugation with glycine and taurine was not observed. As glucuronides are poorly absorbed from the gut, it is proposed that the hepatic biotransformation of nor-ursodeoxycholate to a glucuronide rather than to a glycine amidate in the liver prevented its accumulation in the bile acid pool. Thus, shortening the side chain of ursodeoxycholate by a single carbon atom resulted in a bile acid with novel metabolism, which when administered chronically, does not accumulate in the enterohepatic circulation and does not cause hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3710068     DOI: 10.1016/0016-5085(86)90457-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis.

Authors:  Vyacheslav U Buko; Oxana Y Lukivskaya; Elena E Naruta; Elena B Belonovskaya; Horst-Dietmar Tauschel
Journal:  J Clin Exp Hepatol       Date:  2014-02-21

2.  Unexpected dilatation of the common bile duct after methyl tertiary butyl ether (MTBE) in rabbits. Possible implications to findings in man.

Authors:  R Tritapepe; C Pozzi; P Caspani; C Di Padova
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

Review 3.  A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Authors:  Elizabeth C Goode; Simon M Rushbrook
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

Review 4.  Activation of muscarinic receptor signaling by bile acids: physiological and medical implications.

Authors:  Jean-Pierre Raufman; Kunrong Cheng; Piotr Zimniak
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

5.  Functional and structural features of cholangiocytes in health and disease.

Authors:  Luca Maroni; Bai Haibo; Debolina Ray; Tianhao Zhou; Ying Wan; Fanyin Meng; Marco Marzioni; Gianfranco Alpini
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-07-01

6.  Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.

Authors:  Peter Fickert; Marion J Pollheimer; Dagmar Silbert; Tarek Moustafa; Emina Halilbasic; Elisabeth Krones; Franziska Durchschein; Andrea Thüringer; Gernot Zollner; Helmut Denk; Michael Trauner
Journal:  J Hepatol       Date:  2013-01-29       Impact factor: 25.083

Review 7.  Biology of Cholangiocytes: From Bench to Bedside.

Authors:  Kyo-Sang Yoo; Woo Taek Lim; Ho Soon Choi
Journal:  Gut Liver       Date:  2016-09-15       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.